A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28547536)

Published in Drugs R D on May 25, 2017

Authors

Satoru Oka¹^,2, Yoko Obata³^,4^,5, Kenta Torigoe¹^,2, Miki Torigoe¹^,2, Shinichi Abe¹^,2, Kumiko Muta¹, Yuki Ota¹^,2, Mineaki Kitamura¹^,6, Satoko Kawasaki¹, Misaki Hirose¹, Tadashi Uramatsu¹, Hiroshi Yamashita⁷, Hideyuki Arai⁸, Hiroshi Mukae², Tomoya Nishino¹^,2

Author Affiliations

1: Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.
2: Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.
3: Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan. yobata@nagasaki-u.ac.jp.
4: Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan. yobata@nagasaki-u.ac.jp.
5: Medical Educational Development Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan. yobata@nagasaki-u.ac.jp.
6: Department of Blood Purification, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.
7: Department of Nephrology, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Nagasaki, 856-8562, Japan.
8: Department of Nephrology, Japan Community Health Care Organization Isahaya General Hospital, 24-1 Eishouhigashi-machi, Isahaya, Nagasaki, 854-8501, Japan.

Articles cited by this ↗

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int (2004) 2.30

Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 1.92

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial (2010) 1.71

Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol (2005) 1.68

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron (1997) 1.63

Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int (2008) 1.54

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet (2006) 1.09

Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis (2000) 1.09

Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis (1997) 1.08

The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol (2006) 1.07

Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol (2009) 1.07

Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis. Ther Apher Dial (2015) 0.83

Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study). Ther Apher Dial (2013) 0.82

Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. Nephrology (Carlton) (2015) 0.79

Neuraminidase-like activity in sera of uremic anemic patients. Nephron (1984) 0.79

Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis. Nephrology (Carlton) (2015) 0.79

Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. Int J Hematol (2016) 0.79

Increased plasma glycosidase and protease activity in uraemia: possible role in the aetiology of the anaemia of chronic renal failure. Clin Chim Acta (1985) 0.78